930785-40-3

Usage

Uses

Used in Pharmaceutical Research and Development:
TERT-BUTYL 1-OXA-4,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE is used as a synthetic intermediate for the development of novel drug compounds. Its unique molecular structure allows for the exploration of new therapeutic agents with potential applications in various medical fields.
Used in Drug Discovery and Medicinal Chemistry:
In the field of drug discovery and medicinal chemistry, TERT-BUTYL 1-OXA-4,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE is utilized for its potential to exhibit a range of pharmacological activities. Its complex molecular architecture provides a foundation for the design and synthesis of new chemical entities with therapeutic potential.
Used in Pharmaceutical Industry:
TERT-BUTYL 1-OXA-4,9-DIAZASPIRO[5.5]UNDECANE-9-CARBOXYLATE is used in the pharmaceutical industry as a key component in the synthesis and characterization of new drug candidates. Its unique properties and potential applications make it an important tool for researchers working to advance the development of innovative medications.

InChI:InChI=1/C13H24N2O3/c1-12(2,3)18-11(16)15-7-4-13(5-8-15)10-14-6-9-17-13/h14H,4-10H2,1-3H3

Upstream product

• 1160247-07-3 tert-butyl 3-oxo-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate 
• 392331-66-7 4-aminomethyl-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 147804-30-6 1-oxa-6-aza-spiro-[2.5]octane-6-caboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 819800-93-6 tert-butyl 4-hydroxy-4-(nitromethyl)-piperidine-1-carboxylate 
• 41661-47-6 piperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1097920-69-8 4-benzyl 9-tert-butyl 1-oxa-4,9-diazaspiro[5.5]undecane-4,9-dicarboxylate 

Downstream Products

• 1352926-03-4 tert-butyl 4-benzyl-1-oxa-4,9-diazaspiro[5.5]undecane-9-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or sa

1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS

The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

AMIDE DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opioid receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain. (formula 1) wherein Y is (formula 2) or (formula 3) ? n is 1 or 2; ? q is 1, 2, 3, 4, 5 or 6; ? X is a bond, -C(O)O-, -C(0)NR 8-, -C(O)-, -0- or -C(R 4R 4.)-; ? R 1is C(0)R 5or S(O) 2R 5.

The discovery of new spirocyclic muscarinic M3 antagonists

The optimisation of a new series of high potency muscarinic M3 antagonists, derived from high throughput screening library hit is described.